# CVE-2019-17331: TIBCO EBX Add-on For Data Exchange Cross-Site Scripting Vulnerabilities

> Authenticated users can perform stored cross-site scripting attacks in the Data Exchange Web Interface of TIBCO EBX Add-ons.

- **Severity:** High 7.3 (`CVSS:3.0/AV:N/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N`)
- **Exploited in the wild:** Not known
- **Login needed:** Any signed-in user
- **Attackable:** Over the internet
- **Victim action needed:** A user has to click or open something
- **Fix available:** No
- **Published:** 12 Nov 2019
- **Updated:** 17 Sep 2024
- **Also known as:** GHSA-mrhx-hcg2-5p6w

## What is CVE-2019-17331?

CVE-2019-17331 is a high-severity cross-site scripting vulnerability in TIBCO EBX Add-ons, published on 12 Nov 2019. Any signed-in user can exploit it over the network, and only if a user opens a file or follows a link.

### Official description

The Data Exchange Web Interface component of TIBCO Software Inc.'s TIBCO EBX Add-ons contains a vulnerability that theoretically allows authenticated users to perform stored cross-site scripting (XSS) attacks. Affected releases are TIBCO Software Inc.'s TIBCO EBX Add-ons: versions up to and including 3.20.13, version 4.1.0.

Weakness: CWE-79 (Improper Neutralization of Input During Web Page Generation)

## Which versions are affected by CVE-2019-17331?

It affects 1 product.


Products: Tibco Ebx Add-Ons.

## How do I fix CVE-2019-17331?

No fix has been published for CVE-2019-17331 yet. Limit exposure of the affected software until one is available.

## Is CVE-2019-17331 being exploited?

There is no known exploitation of CVE-2019-17331 in the wild and no public exploit code.

## Other vulnerabilities in TIBCO EBX Add-ons

- [CVE-2023-26216](https://insights.sbomify.com/CVE-2023-26216/): TIBCO EBX Add-ons Arbitrary File Write (critical 9.1)
- [CVE-2023-26217](https://insights.sbomify.com/CVE-2023-26217/): TIBCO EBX Add-ons SQL Injection Vulnerability (high 8.8)
- [CVE-2022-41566](https://insights.sbomify.com/CVE-2022-41566/): TIBCO EBX Add-ons Cross Site Scripting (XSS) Vulnerability (high 8.7)
- [CVE-2022-30578](https://insights.sbomify.com/CVE-2022-30578/): TIBCO EBX Add-ons Stored XSS vulnerability (high 8.0)
- [CVE-2023-26215](https://insights.sbomify.com/CVE-2023-26215/): TIBCO EBX® Add-ons Path Traversal (high 7.7)

## Fix prompt for AI coding agents

```text
Check this codebase for CVE-2019-17331 and fix it if it is affected.

What it is: CVE-2019-17331 is a high-severity cross-site scripting vulnerability in TIBCO EBX Add-ons, published on 12 Nov 2019. Any signed-in user can exploit it over the network, and only if a user opens a file or follows a link.
Exploitation: There is no known exploitation of CVE-2019-17331 in the wild and no public exploit code.

Affected product: TIBCO EBX Add-ons. No package-level version data is available, so check the vendor advisory linked from the reference page.

Task:
1. Search the dependency manifests and lockfiles (for example package.json, package-lock.json, requirements.txt, poetry.lock, uv.lock, pom.xml, build.gradle, go.mod, Cargo.lock, Gemfile.lock) and any Dockerfiles for the affected packages, including transitive dependencies.
2. If an affected version is in use, upgrade it to the fixed version for its release line with the project's package manager, so the lockfile is regenerated. Prefer the smallest upgrade that fixes it.
3. If there is no fix, or the upgrade would break the build, do not guess: explain the risk and the safest workaround instead.
4. Run the tests and summarise what changed and why.
5. If nothing in the project is affected, say so and change nothing.

Reference: https://insights.sbomify.com/CVE-2019-17331/ (Markdown: https://insights.sbomify.com/CVE-2019-17331/index.md)
```

## Sources

- CVE record: https://www.cve.org/CVERecord?id=CVE-2019-17331
- NVD: https://nvd.nist.gov/vuln/detail/CVE-2019-17331
- OSV: https://osv.dev/vulnerability/CVE-2019-17331

---
From sbomify Insights: https://insights.sbomify.com/CVE-2019-17331/
Summaries are generated and may contain mistakes; the official description above is the record.